Rallybio vs Silence Therapeutics
RLYB and SLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RLYB and SLN compare
Rallybio grew revenue faster over the last twelve months (−35.6% versus −98.2% for Silence Therapeutics).
Rallybio keeps more of each dollar of sales as profit, with a net margin of 6177% compared with −11277% at Silence Therapeutics.
Rallybio scores higher on the StockData Score (10 against 7 for Silence Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RLYB | SLN |
|---|---|---|
| Size and price | ||
| Market cap | $82.3M | – |
| Share price | $15.29 | $19.80 |
| Change, 1 year | 199% | 190% |
| Change, 5 years | −85.5% | −10.0% |
| Beta (5Y) | 0.01 | 0.81 |
| Employees | 14 | 88 |
| StockData Score | ||
| Total score | 10 (better) | 7 |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 3.4× | – |
| P/S | 190× | – |
| P/B | 0.9× | – |
| Growth | ||
| Revenue growth (TTM) | −35.6% (better) | −98.2% |
| Profitability | ||
| Gross margin | – | 95.0% |
| Operating margin | −5581% (better) | −12344% |
| Net margin | 6177% (better) | −11277% |
| FCF margin | – | −9682% |
| Return on equity | 34.5% (better) | −35.6% |
| Return on invested capital | −718% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 28.87 (better) | 23.94 |
| Altman Z-score | 11.42 | – |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | – | 16.6% |
| Held by insiders | 72.6% | 48.1% |
| Insider net buying, 12 months | $4.2M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 2.6% | – |
Go deeper
- RLYB stock overview
- RLYB income statement
- RLYB valuation and score
- SLN stock overview
- SLN income statement
- SLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.